Genmab A/S Dkk (GNMSF) 169.6500 $GNMSF Daratumumab

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genmab A/S Dkk (GNMSF) 169.6500 $GNMSF

Daratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in Combination with Standard of Care Regimens for Previously Treated Multiple Myeloma
GlobeNewswire - Tue Jul 26, 2:15AM CDT
Company Announcement
GEN: 2.13 (+0.01)

Bristol-Myers Buys Cormorant, Focus on Immuno-Oncology
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:02AM CDT
Bristol-Myers (BMY) acquires a privately held pharma company, Cormorant Pharmaceuticals, to bolster its immuno-oncology pipeline.
INVA: 11.44 (+0.02), PFE: 36.83 (+0.05), BMY: 75.06 (-0.50)

Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 11:17AM CDT
Genmab (GNMSF) announced that CHMP issued a negative opinion for Arzerra as a maintenance therapy for relapsed chronic lymphatic leukemia.
JNJ: 125.15 (+0.26), ANIP: 59.49 (+0.80), NVS: 83.02 (-0.44)

Genmab Provides Update on Marketing Authorization Application for Arzerra(r) (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL
GlobeNewswire - Thu Jun 23, 9:33AM CDT
-- Committee for Medicinal Products for Human Use (CHMP) issues negative opinion for Arzerra for maintenance treatment of patients with relapsed CLL
GEN: 2.13 (+0.01), NVS: 83.02 (-0.44)

7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 49.92 (-0.07), JNJ: 125.15 (+0.26), PFE: 36.83 (+0.05), LGND: 134.25 (+0.65), BMY: 75.06 (-0.50), AMPH: 16.57 (unch)

Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis
GlobeNewswire - Thu Jun 02, 12:50AM CDT
Company Announcement

Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collaboration with Janssen
GlobeNewswire - Mon May 30, 10:00AM CDT
Company Announcement

Genmab Announces European Conditional Marketing Authorization for DARZALEX(r) (daratumumab) for Multiple Myeloma
GlobeNewswire - Mon May 23, 6:15AM CDT
Company Announcement

Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Wed May 18, 12:29PM CDT
Company Announcement

Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA
GlobeNewswire - Tue May 17, 3:41PM CDT
Company Announcement
GEN: 2.13 (+0.01)

Genmab Announces Financial Results for the First Quarter of 2016
GlobeNewswire - Tue May 10, 10:15AM CDT
Interim Report for the First Quarter of 2016

Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Wed Apr 20, 9:53AM CDT
Company Announcement

Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX(r)
GlobeNewswire - Mon Apr 04, 1:10PM CDT
Company Announcement

Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
GlobeNewswire - Mon Apr 04, 10:48AM CDT
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular features that bind to CD38.

CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) for Relapsed and Refractory Multiple Myeloma
GlobeNewswire - Fri Apr 01, 10:46AM CDT
-- CHMP issued positive opinion for DARZALEX for relapsed and refractory multiple myeloma

First Phase 3 Trial of Daratumumab in Combination with Standard Therapy in Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint in Planned Interim Analysis
PR Newswire - Wed Mar 30, 11:22AM CDT
Janssen Research & Development, LLC announced today positive results of a pre-planned interim analysis of the Phase 3 MMY3004 (CASTOR) trial evaluating the efficacy and safety of daratumumab, a CD38-directed monoclonal antibody (mAb), in combination with bortezomib and dexamethasone, compared to bortezomib and dexamethasone alone, in patients with relapsed or refractory multiple myeloma. The interim analysis, conducted by an Independent Data Monitoring Committee (IDMC), found that the daratumumab combination treatment regimen improved progression-free survival (PFS) compared with bortezomib and dexamethasone alone, achieving the primary study endpoint (p < 0.0001). Based on the recommendation of the IDMC, the study will be stopped early. Study patients originally assigned to the standard treatment group (bortezomib plus dexamethasone) will be offered the option of receiving daratumumab following confirmed disease progression. All patients continue to be followed for long-term safety and overall survival.

Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Wed Mar 30, 11:19AM CDT
Company Announcement

J&J, Roche Tie Up to Study Dual Immunotherapy Combination
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:40PM CDT
Johnson & Johnson (JNJ) inks a clinical trial deal with Roche (RHHBY) to assess dual monoclonal antibody combination therapy.
JNJ: 125.15 (+0.26), AMGN: 167.67 (+1.11)

Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma
GlobeNewswire - Mon Mar 21, 12:23PM CDT
Company Announcement
GEN: 2.13 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 300

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 349

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 113

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

T. Rowe Price OHA Credit Fund Reports Strong Q2 Performance

Updated Category News Views 146

Financial Performance Overview T. Rowe Price OHA Select Private Credit Fund (NASDAQ: OCREDIT) recently reported its financial results for the quarter ended June 30, 2025. The fund declared total distributions amounting to $0.81 per share for this period. This reflects the growing significance of private credit as a financing solution in today's credit markets. Investment...

Continue Reading
Toll Brothers Unveils Luxurious Townhome Community in Armonk

Updated Category News Views 222

Discover the Enclave at Armonk Located in Armonk, the newly launched Enclave at Armonk invites homebuyers to experience luxury living blended with convenience. This new community by Toll Brothers represents a significant addition to the Westchester County real estate market, bringing elegant townhome designs that promise sophistication and comfort. A Closer Look at the...

Continue Reading
XAI Octagon Trust Expands Opportunities with New Preferred Shares

Updated Category News Views 108

XAI Octagon Trust Issues Convertible Preferred Shares XAI Octagon Floating Rate & Alternative Income Trust (NYSE:XFLT), a diversified closed-end management investment company, has made a significant move by announcing the issuance and sale of 400,000 shares of its 6.95% Series II 2029 Convertible Preferred Shares. This initiative enhances the Trust's capital resources and...

Continue Reading
Endeavour Mining's Recent Share Buyback Activity Overview

Updated Category News Views 208

Endeavour Mining Announces Recent Share Buyback In a significant move for shareholders, Endeavour Mining plc (LSE: EDV, TSX: EDV) has disclosed its recent buyback of ordinary shares. These transactions showcase the company's ongoing commitment to enhancing shareholder value and demonstrate a strategic approach to managing its equity. Details of the Share Buyback Endeavour...

Continue Reading
Sleep Awareness Week 2025: Importance of Quality Sleep

Updated Category News Views 459

National Sleep Foundation Announces 2025 Dates for Sleep Awareness Week Today, the National Sleep Foundation (NSF) has shared that Sleep Awareness Week in 2025 will be observed from March 9 to March 15. This annual campaign aims to highlight the critical role sleep plays in promoting health and overall well-being, encouraging the public to prioritize high-quality sleep....

Continue Reading